Expression of Hedgehog signalling molecules in microcystic adnexal carcinoma.


Journal

Clinical and experimental dermatology
ISSN: 1365-2230
Titre abrégé: Clin Exp Dermatol
Pays: England
ID NLM: 7606847

Informations de publication

Date de publication:
Aug 2021
Historique:
revised: 05 02 2021
received: 28 10 2020
accepted: 11 03 2021
pubmed: 14 3 2021
medline: 23 11 2021
entrez: 13 3 2021
Statut: ppublish

Résumé

Microcystic adnexal carcinoma (MAC) is a rare skin neoplasm that has not been characterized on a molecular basis. To assess expression profiles of Hedgehog (HH) signalling molecules in MAC and control tumours. Immunohistochemistry was performed for Sonic Hedgehog (SHH), Indian Hedgehog (IHH), Patched 1 (PTCH1) and Smoothened (SMO) on patient MAC tissue (n = 26) and control tumour tissue, including syringoma (SyG; n = 11), trichoepithelioma (TE; n = 11) and basal cell carcinoma (BCC; n = 12) tissues. Patched 1 and SMO immunoreactivity was significantly higher in BCC than in SyG, TE or MAC (P < 0.001 and P < 0.03, respectively). The highest IHH expression was observed in BCC and TE compared with SyG and MAC (P < 0.04). Notably, the highest SHH protein expression was observed in SyG compared with MAC, TE and even BCC (P < 0.001). In patients with MAC, SMO immunoreactivity significantly (r = 0.51; P < 0.01) correlated with PTCH1 expression. Further correlation studies did not show significant associations between the HH expression markers assessed (P > 0.05). Our results indicate that alterations of the HH signalling are unlikely to play a major role in the pathogenesis of MAC, which is in contrast to the morphologically similar BCC and TE. Our observation provides additional information to the limited molecular pathology knowledge on this rare tumour.

Sections du résumé

BACKGROUND BACKGROUND
Microcystic adnexal carcinoma (MAC) is a rare skin neoplasm that has not been characterized on a molecular basis.
AIM OBJECTIVE
To assess expression profiles of Hedgehog (HH) signalling molecules in MAC and control tumours.
METHODS METHODS
Immunohistochemistry was performed for Sonic Hedgehog (SHH), Indian Hedgehog (IHH), Patched 1 (PTCH1) and Smoothened (SMO) on patient MAC tissue (n = 26) and control tumour tissue, including syringoma (SyG; n = 11), trichoepithelioma (TE; n = 11) and basal cell carcinoma (BCC; n = 12) tissues.
RESULTS RESULTS
Patched 1 and SMO immunoreactivity was significantly higher in BCC than in SyG, TE or MAC (P < 0.001 and P < 0.03, respectively). The highest IHH expression was observed in BCC and TE compared with SyG and MAC (P < 0.04). Notably, the highest SHH protein expression was observed in SyG compared with MAC, TE and even BCC (P < 0.001). In patients with MAC, SMO immunoreactivity significantly (r = 0.51; P < 0.01) correlated with PTCH1 expression. Further correlation studies did not show significant associations between the HH expression markers assessed (P > 0.05).
CONCLUSION CONCLUSIONS
Our results indicate that alterations of the HH signalling are unlikely to play a major role in the pathogenesis of MAC, which is in contrast to the morphologically similar BCC and TE. Our observation provides additional information to the limited molecular pathology knowledge on this rare tumour.

Identifiants

pubmed: 33714217
doi: 10.1111/ced.14634
doi:

Substances chimiques

Hedgehog Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1052-1057

Informations de copyright

© 2021 The Authors. Clinical and Experimental Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.

Références

Ahn CS, Sangüeza OP. Malignant sweat gland tumors. Hematol Oncol Clin North Am 2019; 33: 53-71.
King BJ, Tolkachjov SN, Winchester DS et al. Demographics and outcomes of microcystic adnexal carcinoma. J Am Acad Dermatol 2018; 79: 756-8.
Gordon S, Fischer C, Martin A et al. Microcystic adnexal carcinoma: a review of the literature. Dermatol Surg 2017; 43: 1012-16.
Yu JB, Blitzblau RC, Patel SC et al. Surveillance, epidemiology, and end results (SEER) database analysis of microcystic adnexal carcinoma (sclerosing sweat duct carcinoma) of the skin. Am J Clin Oncol 2010; 33: 125-7.
Li C, Chi S, Xie J. Hedgehog signaling in skin cancers. Cell Signal 2011; 23: 1235-43.
Taipale J, Cooper M, Maiti T, Beachy P. Patched acts catalytically to suppress the activity of Smoothened. Nature 2002; 418: 892-7.
Hafner C, Schmiemann V, Ruetten A et al. PTCH mutations are not mainly involved in the pathogenesis of sporadic trichoblastomas. Hum Pathol 2007; 38: 1496-500.
Nilsson M, Undèn AB, Krause D et al. Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1. Proc Natl Acad Sci U S A 2000; 97: 3438-43.
Wohlfahrt C, Ternesten A, Sahlin P et al. Cytogenetic and fluorescence in situ hybridization analyses of a microcystic adnexal carcinoma with del(q23q25). Cancer Genet Cytogenet 1997; 98: 106-10.
Chen MB, Laber DA. Metastatic microcystic adnexal carcinoma with DNA sequencing results and response to systemic antineoplastic chemotherapy. Anticancer Res 2017; 37: 5109-11.
Chan MP, Plouffe KR, Liu CJ et al. Next-generation sequencing implicates oncogenic roles for p53 and JAK/STAT signaling in microcystic adnexal carcinomas. Mod Pathol 2020; 33: 1092-103.
Smith KJ, Williams J, Corbett D, Skelton H. Microcystic adnexal carcinoma: an immunohistochemical study including markers of proliferation and apoptosis. Am J Surg Pathol 2001; 25: 464-71.
Cavicchioli Buim ME, Gurgel CA, Gonçalves Ramos EA et al. Activation of sonic hedgehog signaling in oral squamous cell carcinomas: a preliminary study. Hum Pathol 2011; 42: 1484-90.
Moya-Martínez C, Torre-Castro J, Mendoza Cembranos D et al. Microcystic adnexal carcinoma with germinative follicular differentation. J Cutan Pathol 2020; 48: 123-7.
Zito PM, Mazzoni T. Microcystic adnexal carcinoma. 2020 29 September. In: StatPearls Treasure Island: StatPearls Publishing, 2020. Available at: https://www.ncbi.nlm.nih.gov/books/NBK557857/ (accessed 26 March 2021).

Auteurs

T Gambichler (T)

Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany.

I Hartenstein (I)

Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany.

M Dreißigacker (M)

Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany.

E Stockfleth (E)

Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany.

M Stücker (M)

Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany.

J Schaller (J)

Dermatopathology Duisburg, Duisburg, Germany.

H-J Schulze (HJ)

Fachklinik Hornheide, Skin Cancer Center, Department of Dermatology and Dermato-Histo-Pathology, Münster, Germany.

J C Becker (JC)

Translational Skin Cancer Research, German Cancer Consortium (DKTK) Partner Site Essen/Düsseldorf, Department of Dermatology, University Duisburg-Essen, Essen, Germany.
Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany.

H U Käfferlein (HU)

Institute for Prevention and Occupational Medicine of the German Social Accident Insurances, Ruhr-University Bochum (IPA), Bochum, Germany.

T Brüning (T)

Institute for Prevention and Occupational Medicine of the German Social Accident Insurances, Ruhr-University Bochum (IPA), Bochum, Germany.

K Lang (K)

Institute for Prevention and Occupational Medicine of the German Social Accident Insurances, Ruhr-University Bochum (IPA), Bochum, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH